Call +1 858 457-8383 Fax +1 858 457-8484

Rebeccamycin

BVT-0139-C250 250 µg $105.00
BVT-0139-M001 1 mg $315.00
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +1 858 457-8383
Fax +1 858 457-8484
Contact Us!

Additional Information

Product Data
Synonyms NSC 359079; BRN 4732638
Properties
Formula C27H21Cl2N3O7
MW 570.4
CAS 93908-02-2
Source/Host Chemicals Isolated from Streptomyces sp.
Purity ≥98% (HPLC)
Appearance Yellow solid.
Solubility Soluble in DMSO.
Identity Determined by 1H-NMR.
Origin Manufactured by BioViotica.
InChi Key QEHOIJJIZXRMAN-UMHCKEELSA-N
Product Type Chemical
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C. After reconstitution, prepare aliquots and store at -20°C.
Documents
MSDS Download Document Download

Product Description

  • Antibiotic.
  • Weak topoisomerase I (Topo I) inhibitor.
  • Structurally similar to staurosporine.
  • Does not show any inhibitory activity against protein kinases.
  • Shows significant antitumor properties in vitro (IC50 = 480 nM against mouse B16 melanoma cells and IC50 = 500 nM against P388 leukemia cells).

Product References

  1. Production and biological activity of rebeccamycin, a novel antitumor agent: J.A. Bush, et al.; J. Antibiot. (Tokyo) 40, 668 (1987)
  2. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin: C. Bailly, et al.; Biochemistry 36, 3917 (1997)
  3. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group: F. Anizon, et al.; J. Med. Chem. 40, 3456 (1997)
  4. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition: C. Bailly, et al.; Chem. Biol. 6, 277 (1999)
  5. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitor: C. Marminon, et al.; Mol Pharmacol 74, 1620-1629 (2008)
  6. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers: A. Dowlati, et al.; Cancer Chemother Pharmacol 65, 73-78 (2009)
  7. New progress of researches in carbazole compounds: F. Zhang, et al.; Chinese J. Org. Chem. 30, 783 (2010)
No reviews for this product yet.